Tyrima was well tolerated with no clinically significant adverse events even at the highest dose of 120 mg. Tyrima achieved high plasma concentrations that increased linearly with dose, and the favourable pharmacokinetic half-life should permit once or twice daily dosing. None of the safety and tolerability issues commonly associated with conventional monoamine oxidase A inhibitors (MAOIs) were seen in this study.
I
n contrast to the leading antidepressants available today that affect only the single neurotransmitter serotonin, Tyrima™ works by elevating the levels of three key neurotransmitters (serotonin, norepinephrine and dopamine) that affect mood and anxiety – the triple action mechanism has the potential for enhanced efficacy while the selective and reversible nature of RIMAs is intended to avoid toxic side effects.
Once approved, Tyrima™ will be the first RIMA antidepressant available in the U.S. market.
CeNeRx - a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system - has worldwide rights to develop and commercialize Tyrima™, which has patent protection through 2026.
Read the full press release.
Comment Preview